This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC. The management of non-muscle invasive bladder cancer (NMIBC) ...

In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT. Using PSMA-PET imaging and ...

Pastuszak discusses the evolving nature of understanding how testosterone therapy post-radiation for prostate cancer may beneficial or harmful to patients, and how to navigate the decision. Overall, a ...

Farah Rahman, MD, MPH, highlights a pilot study on the use of wearable biofeedback technology to better understand and address burnout among urology residents. Sudha Jayaraman, MD, MSc, FACS, recaps a ...

"We knew that the MS or momentary squeeze pump, originally designed at AMS was a fine device, but it did have some issues. We thought we could make it even better," says Ronald A. Morton, MD. The ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Apalutamide shows a 23% reduction in mortality risk at 24 months compared to enzalutamide in mCSPC patients. The study's findings are consistent with the TITAN trial, confirming apalutamide's survival ...

The Avvio ELS has received FDA breakthrough device designation, enhancing its development and review process for treating ureteral stones. The system uses microbubble-enhanced acoustic cavitation ...

Cretostimogene grenadenorepvec showed a 75.5% complete response rate in high-risk BCG-unresponsive NMIBC patients, with durable responses at 12 and 24 months. The treatment was well-tolerated, with ...

A recap of the FDA submissions and regulatory decisions in urology from June 2026. Welcome to Urology Times’® monthly FDA update! June 2026 brought a wave of regulatory developments across the urology ...

The CAPItello-280 trial was terminated due to unlikely achievement of primary endpoints in metastatic castration-resistant prostate cancer. Capivasertib, an ATP-competitive AKT inhibitor, showed a ...

The Glean Urodynamics System offers wireless, catheter-free monitoring, improving accuracy and comfort for LUTD patients. Developed with the Cleveland Clinic, the system allows natural voiding, ...